Importantly, SIGLEC‐1 expression has been leveraged for immunotherapy: ganglioside‐containing liposomes targeting SIGLEC‐1 on tDCs have been used in a nanovaccine platform incorporating the TLR7/8 agonist R848 and tumor antigen payloads. Here, SIGLEC1 is linked to neoplasm.